Alvotech (NASDAQ:ALVO – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday, Wall Street Zen reports.
A number of other research firms have also recently commented on ALVO. Bank of America assumed coverage on Alvotech in a research report on Monday, August 24th. They set a “buy” rating and a $7.00 target price on the stock. Jefferies Financial Group started coverage on Alvotech in a report on Tuesday, November 10th. They issued a “buy” rating and a $9.00 price target for the company. Zacks Research downgraded Alvotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Finally, UBS Group set a $8.00 price objective on Alvotech in a report on Wednesday, September 16th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Alvotech currently has a consensus rating of “Hold” and a consensus target price of $8.40.
Check Out Our Latest Analysis on Alvotech
Alvotech Stock Performance
ALVO stock opened at $4.41 on Friday. The firm’s fifty day moving average is $5.21 and its 200 day moving average is $4.20. Alvotech has a one year low of $2.94 and a one year high of $6.53.
Alvotech (NASDAQ:ALVO – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $111.60 million during the quarter, compared to analysts’ expectations of $123.45 million. As a group, research analysts expect that Alvotech will post -0.01 earnings per share for the current fiscal year.
Institutional Trading of Alvotech
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of Alvotech during the second quarter worth about $6,376,000. Royce & Associates LP purchased a new position in Alvotech in the 3rd quarter valued at about $3,817,000. Marshall Wace LLP purchased a new position in Alvotech in the 3rd quarter valued at about $2,326,000. Lighthouse Investment Partners LLC purchased a new position in Alvotech in the 3rd quarter valued at about $725,000. Finally, Ulland Investment Advisors LLC boosted its holdings in Alvotech by 5.0% in the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock worth $667,000 after buying an additional 5,500 shares during the last quarter.
About Alvotech
Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.
Recommended Stories
- Five stocks we like better than Alvotech
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
